Latest filing published 05 Oct 2018 for Aclaris Therapeutics, Inc., €86k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 4 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -91.3%Entry US$13.26 · Close at T+365 US$1.16
- -94.0%Entry US$15.94 · Close at T+365 US$0.96
- -94.2%Entry US$16.02 · Close at T+365 US$0.93
- -64.0%Entry US$17.35 · Close at T+365 US$6.25
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Stephen A. Tullman: trading record in brief
This profile gathers the share dealings of Stephen A. Tullman in Aclaris Therapeutics, Inc. In total, 12 filings cover trades dated from 13 October 2015 to 4 October 2018.
On the market, this insider has only ever bought: 4 purchases, €621k in total. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. 2018 to date brings 4 purchases and no sales.
In size, the median ticket on the buying side is €87k. Of 4 purchases, 1 formed part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. Looking at 4 purchases old enough to measure, the stock rose over the following 90 days in 25% of cases; the median change was -43.7%. This is a record of the past, not a forecast.
On 5 October 2018 came the latest disclosure, an open-market purchase for €86k in Aclaris Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Stephen A. Tullman
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 7,100 shares@ US$14.0013.9% of flowCommon StockSEC:0001209191-18-054397:0Canonical exit: 2 Jan 2019 (T+90)
- 6,600 shares@ US$15.0013.8% of flowCommon StockSEC:0001209191-18-048503:0Canonical exit: 21 Nov 2018 (T+90)
- 6,250 shares@ US$15.9714.2% of flowCommon StockSEC:0001209191-18-047417:0Canonical exit: 13 Nov 2018 (T+90)
- 26,700 shares@ US$16.5458.1% of flowCommon StockSEC:0001209191-18-024356:0Canonical exit: 5 Jul 2018 (T+90)
- 94,151 shares0Common StockSEC:0001209191-18-020924:0
- 9,018 shares0Common StockSEC:0001209191-18-020924:1
- 521,739 shares0Common StockSEC:0001209191-16-142071:0
- 116,999 shares0Common StockSEC:0001209191-16-142071:1
- 144,153 shares0Common StockSEC:0001209191-16-142071:2
- 50,002 shares0Common StockSEC:0001209191-16-142071:3
- 4,790 shares0Common StockSEC:0001209191-16-142071:4
- 46,188 sharesCommon StockSEC:0001209191-15-075193:0
12 of 12 declarations
